Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Columnist Candace Semien applies the concept of radical responsibility to managing lupus and other chronic health conditions.

A NEW Swedish study has found that menopausal hormone therapy (MHT) may be associated with an increased risk of developing ...

The New England Journal of Medicine has published a detailed analysis of Genentech’s positive results from the Phase III REGENCY study of Gazyva® (Obinutuzumab) for people with active lupus nephritis ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

People with lupus are at an increased risk of depression. Lupus is a chronic condition with recurring symptoms that can ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...